zolmitriptan 2.5mg orodispersible tablets sugar free
accord-uk ltd - zolmitriptan - orodispersible tablet - 2.5mg
zolmitriptan 5mg orodispersible tablets sugar free
accord-uk ltd - zolmitriptan - orodispersible tablet - 5mg
zolmitriptan sanofi 2.5 milligram film coated tablet
sanofi-aventis ireland limited t/a sanofi - zolmitriptan - film coated tablet - 2.5 milligram
zolmitriptan sanofi 2.5 milligram orodispersible tablet
sanofi-aventis ireland limited t/a sanofi - zolmitriptan - orodispersible tablet - 2.5 milligram
zolmitriptan teva 2.5 milligram orodispersible tablet
teva pharma b.v. - zolmitriptan - orodispersible tablet - 2.5 milligram - selective serotonin (5ht1) agonists
zomig- zolmitriptan tablet zomig zmt- zolmitriptan tablet, orally disintegrating
amneal pharmaceuticals - zolmitriptan (unii: 2fs66th3yw) (zolmitriptan - unii:2fs66th3yw) - zolmitriptan 2.5 mg - zomig is indicated for the acute treatment of migraine with or without aura in adults. limitations of use zomig is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with the use of zomig in pregnant women. in reproductive toxicity studies in rats and rabbits, oral administration of zolmitriptan to pregnant animals resulted in embryolethality and fetal abnormalities (malformations and variations) at clinically relevant exposures (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the estimated rates of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. clinical considerations disease-associated maternal and/or embryo/fetal risk published data have suggested that women with migraine may be at increased risk of pree
zomig- zolmitriptan spray, metered
amneal pharmaceuticals - zolmitriptan (unii: 2fs66th3yw) (zolmitriptan - unii:2fs66th3yw) - zolmitriptan 5 mg - zomig nasal spray is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. limitations of use zomig is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with the use of zomig in pregnant women. in reproductive toxicity studies in rats and rabbits, oral administration of zolmitriptan to pregnant animals resulted in embryolethality and fetal abnormalities (malformations and variations) at clinically relevant exposures (see data) . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the estimated rates of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine. clinical considerations disease-associated maternal and/or embryo/fetal risk published data have sugges
zolmitriptan 2.5mg orodispersible tablets sugar free
arrow generics ltd - zolmitriptan - orodispersible tablet - 2.5mg
zolmitriptan 5mg orodispersible tablets sugar free
arrow generics ltd - zolmitriptan - orodispersible tablet - 5mg
zolmitriptan 2.5mg orodispersible tablets sugar free
zentiva pharma uk ltd - zolmitriptan - orodispersible tablet - 2.5mg